Life sciences cloud software provider Veeva Systems (NYSE: VEEV) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 16.3% year on year to $882.9 million. Guidance for next quarter’s revenue was better than expected at $903.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $2.24 per share was 4.9% above analysts’ consensus estimates.

Is now the time to buy VEEV? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Veeva Systems’ first quarter saw meaningful progress across its core business lines, with management attributing the results to broad-based customer demand and product execution in both R&D and commercial segments. CEO Peter Gassner highlighted the launch of Veeva’s Falcon platform as a key milestone, describing it as a shift toward “agentic labor”—using AI agents to automate specialized industry tasks. Strong service execution and continued innovation in measurement tools like Crossix also contributed, with management noting that market appetite for digital and AI-driven solutions remains robust.

Looking ahead, Veeva’s updated guidance is anchored by expectations for continued AI adoption, new product rollouts, and expanded customer engagement from recent acquisitions. Management views the integration of platforms like Falcon and Ostro as central to delivering industry-specific automation, with Gassner emphasizing, “Falcon is just going to deliver value. It’s going to be great revenue for Veeva, but it’s going to deliver value far above and beyond that for the industry.” The company is also prioritizing investments in product engineering and consulting to maintain technology leadership and support the scaling of AI-powered offerings.

Key Insights from Management’s Remarks

Management attributed the quarter’s growth to accelerated AI product development, increased digital engagement, and diversification in both R&D and commercial services.

• Falcon platform launch: Veeva introduced Falcon, an AI-driven platform targeting "agentic labor"—automation of repetitive, regulated industry tasks previously performed by humans. Management described Falcon as a disruptive shift, with initial focus on document processing for clinical trials and safety case triage.
• Crossix momentum: The Crossix measurement and analytics business continued to gain share, driven by pharma customers’ rising digital marketing spend and Veeva’s investment in measuring emerging channels like OpenEvidence and Meta. Management expects Crossix to remain a durable growth engine.
• Ostro acquisition integration: Veeva’s acquisition of Ostro aims to enhance brand engagement for pharma clients by enabling compliant, instantaneous information exchange between biopharma companies, healthcare professionals, and patients. Management underscored the strategic fit and long-term growth potential of Ostro within the Commercial Cloud suite.
• CRM migration wins: Veeva secured notable customer wins in CRM, including global agreements with Teva and Merck KGaA, and reported a win rate above 80% for Vault CRM migrations. Over 150 customers are now live on Vault CRM, with growing adoption of embedded AI capabilities.
• Professional services strength: The company delivered record services revenue, citing robust demand for consulting work beyond implementations, including digital events and CRM migration support. Management cautioned, however, that services revenue should not be seen as a leading indicator of subscription growth due to its varied composition.

Drivers of Future Performance

Veeva’s outlook centers on scaling AI-powered platforms, expanding digital engagement capabilities, and maintaining disciplined investment in product innovation.

• AI platform scaling: Management expects Falcon and Vault AI to play a larger role in automating core industry workflows, with initial deployments focused on standard tasks for smaller, nimble biopharma customers. While AI revenue (outside of Ostro) is expected to be modest this year, Veeva sees significant long-term potential as adoption broadens and use cases expand.
• Customer engagement and market expansion: The company is leveraging acquisitions like Ostro and continued momentum in Crossix to deepen relationships with healthcare providers and patients, positioning itself as a comprehensive commercial engagement partner. Management anticipates these platforms will enhance both compliance and customer value as digital channels proliferate.
• Ongoing investments and margin outlook: Veeva will sustain investment in product engineering, consulting, and data infrastructure to support growth in emerging areas. Management acknowledged that services investments may pressure near-term margins, but expects overall efficiency gains and productivity improvements from AI to support long-term profitability.

Catalysts in Upcoming Quarters

In future quarters, StockStory analysts will focus on (1) the pace of Falcon and Vault AI adoption among both small and large biopharma clients, (2) measurable progress in integrating Ostro and scaling its brand engagement capabilities, and (3) continued wins and successful migrations in Vault CRM, especially as remaining top customer decisions unfold. Execution on product innovation and evidence of durable demand in digital analytics will also be important indicators.

Veeva Systems currently trades at $181.43, up from $178.64 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.